The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

AstraZeneca UK Limited
Horizon Place, 600 Capability Green, Luton, Bedfordshire, LU1 3LU
Telephone: +44 (0)1582 836 000
Fax: +44 (0)1582 838 000
Medical Information Direct Line: +44 (0)1582 836 836
Medical Information e-mail: medical.informationuk@astrazeneca.com
Customer Care direct line: +44 (0)1582 837 837
Medical Information Fax: +44 (0)1582 838 003
Need to contact this company?
Summary of Product Characteristics last updated on the eMC: 18/08/2009
SPC Inderal Injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 18/08/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   19-May-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


Section 4.5

Change of text 2nd paragraph to include amiodarone:

Class I anti-arrhythmic drugs (e.g. disopyramide) and amiodarone may have potentiating effect on atrial-conduction time and induce negative inotropic effect.

 

Section 4.8

Revised table.

 

Section 10

Change of revision date to 19 May 2009
Updated on 21/08/2003 and displayed until 18/08/2009
Reasons for adding or updating:
  • Change to section 9 - Date of Renewal of Authorisation
  • Change to section 10 (date of (partial) revision of the text
Updated on 05/12/2002 and displayed until 21/08/2003
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
Updated on 07/11/2002 and displayed until 05/12/2002
Reasons for adding or updating:
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.8 - Undesirable Effects
Updated on 28/11/2001 and displayed until 07/11/2002
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 16/08/2001 and displayed until 28/11/2001
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Updated on 06/09/1999 and displayed until 16/08/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  propranolol hydrochloride


Return to the top of the page

© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk